(Reuters) – Sufferers who expertise recurrence of COVID-19 signs after finishing remedy with Pfizer (NYSE:)’s drug Paxlovid ought to isolate once more for 5 days, the U.S. Facilities for Illness Management and Prevention mentioned in an advisory issued on Tuesday.

Dozens of people have reported rebounding COVID signs on social media or to the U.S. Meals and Drug Administration after taking Paxlovid, however Pfizer suggests the expertise is uncommon. A current rise in COVID circumstances has pushed up use of therapeutics within the nation.

The CDC in its advisory that case reviews counsel that recurrence leads to delicate signs, and there have been no reviews of extreme illness to date. The company nonetheless continues to suggest the oral antiviral drug as a remedy, regardless of the potential of recurrences.

A short return of signs could also be a part of the pure historical past of SARS-CoV-2 an infection in some individuals, no matter remedy with Paxlovid, the company mentioned.

CDC recommends that sufferers with COVID rebound can finish their re-isolation interval after 5 full days if there is no such thing as a fever for twenty-four hours and signs enhance, however such sufferers ought to put on a masks for a complete of 10 days after rebound signs start.